UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Serum biomarkers for evaluation of an adnexal mass for epithelial carcinoma of the ovary, fallopian tube, or peritoneum

Authors
Frederick Rand Ueland, MD
Andrew John Li, MD
Section Editor
Barbara Goff, MD
Deputy Editor
Sandy J Falk, MD, FACOG

INTRODUCTION

Ovarian cancer is the second most common gynecologic malignancy and the most common cause of gynecologic cancer death in the United States [1]. Worldwide in 2008, ovarian cancer was the second most common gynecologic malignancy in developed countries and the third most common gynecologic malignancy (cervical cancer is the most common) in developing countries [2].

Epithelial ovarian cancer, the most common histologic type (95 percent of cases) of ovarian cancer (figure 1), typically presents at an advanced stage, which contributes to its poor prognosis [3]. In addition, a definitive diagnosis of ovarian cancer requires surgery; however, many procedures performed for a pelvic mass ultimately identify a benign adnexal mass.

Use of serum biomarkers for the diagnosis of epithelial ovarian cancer is an active area of investigation. Biomarkers or panels of biomarkers are generally used in combination with each other or with other findings (eg, ultrasound). Only a few biomarkers are commercially available. Cancer antigen 125 (CA 125) has been the focus of most investigations and is used most extensively. Other diagnostic tests for epithelial ovarian cancer include human epididymis protein (HE4), the OVA1 panel, and the Risk of Malignancy Algorithm (ROMA).

There is evidence that high-grade serous epithelial ovarian, fallopian tubal, and peritoneal carcinomas should be considered as a single clinical entity due to their shared clinical behavior and treatment. There is also accumulating evidence of a common pathogenesis for these carcinomas [4]. We will use the term epithelial ovarian cancer to refer to this group of malignancies in the discussion that follows. There is currently no serum biomarker that can distinguish between these types of carcinoma.

Use of serum biomarkers for the diagnosis of epithelial ovarian cancer in women who have an adnexal mass is reviewed here. Related topics are discussed separately, including:

                            

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Apr 20 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10.
  2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.
  3. Lacey JV, Sherman ME. Ovarian neoplasia. In: Robboy's Pathology of the Female Reproductive Tract, 2nd ed., Robboy SL, Mutter GL, Prat J, et al.. (Eds), Churchill Livingstone Elsevier, Oxford 2009. p.601.
  4. Tone AA, Salvador S, Finlayson SJ, et al. The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012; 10:296.
  5. http://seer.cancer.gov/statfacts/html/ovary.html (Accessed on April 24, 2012).
  6. Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005; 193:1630.
  7. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309:883.
  8. http://www.accessdata.fda.gov/cdrh_docs/reviews/K042731.pdf (Accessed on August 20, 2012).
  9. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 2001; 276:27371.
  10. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4:1.
  11. Dorigo O, Berek JS. Personalizing CA125 levels for ovarian cancer screening. Cancer Prev Res (Phila) 2011; 4:1356.
  12. Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem 1993; 39:2509.
  13. Eltabbakh GH, Gupta MK, Belinson JL, et al. Comparison between Centcor CA 125 and CA 125 II assays. Eur J Gynaecol Oncol 1996; 17:504.
  14. Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P. Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. Clin Chem 1998; 44:1417.
  15. Mongia SK, Rawlins ML, Owen WE, Roberts WL. Performance characteristics of seven automated CA 125 assays. Am J Clin Pathol 2006; 125:921.
  16. Grover S, Koh H, Weideman P, Quinn MA. The effect of the menstrual cycle on serum CA 125 levels: a population study. Am J Obstet Gynecol 1992; 167:1379.
  17. http://www.fda.gov/ohrms/dockets/ac/08/briefing/220028-4403b1-02-Proposed%20HE4%20EIA%20Package%20Insert%20%20.pdf (Accessed on August 20, 2012).
  18. Allard J, Somers E, Theil R, Moore RG. Use of a novel biomarker HE4 for monitoring patients with epithelial ovarian cancer (abstract #5535). J Clin Oncol 2008; 26:5535.
  19. Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65:2162.
  20. Menon U, Jacobs I. Tumor markers. In: Principles and Practice of Gynecologic Oncology, Hoskins W, Perez C, Young R (Eds), Lippincott Williams & Wilkins, Philadelphia 2000. p.165.
  21. http://www.medizin.uni-koeln.de/institute/kchemie/Diagnostik/Parameter/Testkits/Roche/CEA.pdf (Accessed on November 14, 2012).
  22. Canney PA, Wilkinson PM, James RD, Moore M. CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125. Br J Cancer 1985; 52:131.
  23. Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15:679.
  24. Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008; 108:402.
  25. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287:1671.
  26. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006; 12:447.
  27. Sutphen R, Xu Y, Wilbanks GD, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:1185.
  28. Zhao C, Annamalai L, Guo C, et al. Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia 2007; 9:1.
  29. Moore LE, Fung ET, McGuire M, et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006; 15:1641.
  30. Hefler-Frischmuth K, Hefler LA, Heinze G, et al. Serum C-reactive protein in the differential diagnosis of ovarian masses. Eur J Obstet Gynecol Reprod Biol 2009; 147:65.
  31. van Haaften-Day C, Shen Y, Xu F, et al. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 2001; 92:2837.
  32. http://www.accessdata.fda.gov/cdrh_docs/reviews/K081754.pdf (Accessed on August 20, 2012).
  33. Zhang Z, Bast RC Jr, Yu Y, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64:5882.
  34. Nosov V, Su F, Amneus M, et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol 2009; 200:639.e1.
  35. Kozak KR, Su F, Whitelegge JP, et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005; 5:4589.
  36. http://www.ova-1.com/physicians/using-ova1 (Accessed on August 20, 2012).
  37. http://www.accessdata.fda.gov/cdrh_docs/pdf10/K103358.pdf (Accessed on August 20, 2012).
  38. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009; 112:40.
  39. Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97:922.
  40. Bast RC Jr, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer 2012; 22 Suppl 1:S5.
  41. http://pathways.nice.org.uk/pathways/ovarian-cancer#path=view%3A/pathways/ovarian-cancer/ovarian-cancer-establishing-the-diagnosis-in-secondary-care.xml&content=view-node%3Anodes-rmi-i-score-and-referral-to-specialist-mdt (Accessed on August 22, 2012).
  42. Manjunath AP, Sujatha K, Vani R. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol Oncol 2001; 81:225.
  43. Tingulstad S, Hagen B, Skjeldestad FE, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996; 103:826.
  44. Tingulstad S, Hagen B, Skjeldestad FE, et al. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999; 93:448.
  45. Yamamoto Y, Yamada R, Oguri H, et al. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol 2009; 144:163.
  46. Geomini P, Kruitwagen R, Bremer GL, et al. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009; 113:384.
  47. Van Calster B, Van Hoorde K, Valentin L, et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ 2014; 349:g5920.
  48. Dodge JE, Covens AL, Lacchetti C, et al. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol 2012; 126:157.
  49. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519.
  50. Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med 1994; 121:124.
  51. Rosenthal AN, Menon U, Jacobs IJ. Screening for ovarian cancer. Clin Obstet Gynecol 2006; 49:433.
  52. Myers ER, Bastian LA, Havrilesky LJ, et al. Management of Adnexal Mass. Evidence Report/Technology Assessment No.130 (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025). AHRQ Publication No. 06-E004, Agency for Healthcare Research and Quality, Rockville, MD February 2006.
  53. Johnson CC, Kessel B, Riley TL, et al. The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol 2008; 110:383.
  54. American College of Obstetricians anf Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002; 100:1413.
  55. Im SS, Gordon AN, Buttin BM, et al. Validation of referral guidelines for women with pelvic masses. Obstet Gynecol 2005; 105:35.
  56. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117:742.
  57. Ueland FR, Desimone CP, Seamon LG, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstet Gynecol 2011; 117:1289.
  58. Vermillion, Inc. Austin, Texas.
  59. Bristow RE, Smith A, Zhang Z, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol 2013; 128:252.
  60. Ware Miller R, Smith A, DeSimone CP, et al. Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol 2011; 117:1298.
  61. Longoria TC, Ueland FR, Zhang Z, et al. Clinical performance of a multivariate index assay for detecting early-stage ovarian cancer. Am J Obstet Gynecol 2014; 210:78.e1.
  62. Goodrich ST, Bristow RE, Santoso JT, et al. The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. Am J Obstet Gynecol 2014; 211:65.e1.
  63. Moore RG, Miller MC, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol 2011; 118:280.
  64. Li F, Tie R, Chang K, et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer 2012; 12:258.
  65. Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer 2011; 104:863.
  66. Modesitt SC, Pavlik EJ, Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003; 102:594.
  67. Bristow RE, Hodeib M, Smith A, et al. Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. Am J Obstet Gynecol 2013; 209:581.e1.